J&J:Tremfya potential in in plaque psoriasis
(CercleFinance.com) - Johnson & Johnson reports that a Phase III study showed that Tremfya (guselkumab) significantly improved skin condition in the majority of adult patients with moderate plaque psoriasis with low body surface area, affecting sensitive areas (scalp, face, skin folds, genitals) and resistant to topical treatments.
Presented at the 2024 Clinical Dermatology Conference, results show that after 16 weeks, 74.2% of Tremfya-treated patients had almost clear or clear skin, compared with 12.4% of placebo-treated patients.
Significant improvements were observed at each treated site, and patients reported an improved quality of life, the company says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Presented at the 2024 Clinical Dermatology Conference, results show that after 16 weeks, 74.2% of Tremfya-treated patients had almost clear or clear skin, compared with 12.4% of placebo-treated patients.
Significant improvements were observed at each treated site, and patients reported an improved quality of life, the company says.
Copyright (c) 2024 CercleFinance.com. All rights reserved.